Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Chitra Hosing, Eric McLaughlin, Zachary Braunstein, Benigno C Valdez, Lai Wei, Uday R Popat, Borje S Andersson, Sumithira Vasu, Karilyn T. Larkin, Samantha Jaglowski, Sam Penza, Ayman Saad, Hannah Choe, Sarah A Wall, Alex Cash, Robin Nakkula, Richard E Champlin, Marcos J.G. de Lima, Dean Anthony Lee, Jonathan E Brammer
Institutions: The University of Texas MD Anderson Cancer Center, The Ohio State University, The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Nationwide Children's Hospital, Abigail Wexner Research Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310117877